Vifor Pharma Leading portfolio and mid-term growth drivers

Transcription

1 Vifor Pharma Leading portfolio and mid-term growth drivers Stefan Schulze CEO VFMCRP Nominated President of the Corporate Executive Committee and COO of the Vifor Pharma Group Media Conference, 14 March 2017 The Galenica Group - Excellence in the healthcare market

2 Vifor Pharma Vision Global Leader in Iron Deficiency, Nephrology and Cardio-Renal Therapies. 2

3 Agenda 1 Experienced management team 2 Proven track record 3 Leading portfolio in target disease areas 4 Three mid-term strategic growth drivers 5 Investments 6 Strong financial performance and 2017 outlook 3

4 Corporate Executive Committee Vifor Pharma Group The future management team Executive Chairman Etienne Jornod President of the Executive Committee and COO Stefan Schulze CEO VFMCRP President Relypsa Chief Commercial Officer Head Business Development CFO Head HR N.N Scott Garland Dario Eklund Chris Springer Colin Bond Michael Puri 4

5 Vifor Pharma Corporate Timeline 1991 Building Iron Portfolio and International Expansion 2010 Becoming Global Leader in Iron Deficiency and Entering into Nephrology 2015 Becoming Global Leader in Nephrology and Entering Cardio-renal Disease Area : Venofer US approval 2007: Launch of Ferinject 2008: Creation of EU affiliates 2009: Acquisition OM Pharma 2010: Creation of VFMCRP 2013: Injectafer - FDA Approval 2013: Launch of Velphoro 2015: Mircera License 2015: Veltassa License 2016: 4 Licensing Deals 2016: Relypsa Acquisition 5

6 Vifor Pharma Leading Portfolio in Iron Deficiency, Nephrology & Cardio-Renal Iron Deficiency Nephrology Cardio-Renal Own Products Restructuring Capital efficiency for sustainability First EVT Innovate investments In-licensed Products Avacopan/ CCX168 CCX140 6

7 Vifor Pharma Three Mid-Term Strategic Growth Drivers A Ferinject : Exploit the Potential through Market Awareness B Vifor Fresenius Medical Care Renal Pharma: Grow and Enhance Value C Veltassa : Build a Blockbuster 7

8 A Vifor Pharma Global Market Leader in intravenous (IV) and oral iron Iron deficiency is the most common nutrient deficiency in the world 1 IV Iron Market Global Iron Market (CHF 2.8 billion) 4 69% Vifor Pharma Up to 4 to 5 billion people may suffer from iron deficiency. 2 Oral iron 52% IV iron 48% Oral Iron Market Iron deficiency anaemia affects approximately 15% of the world population. 3 10% (1) World Health Organization (WHO) Micronutrient deficiencies: Iron deficiency anaemia. Available at Last accessed: 10 November (2) Unicef: Last accessed: 10 November (3) Vos T Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries : a systematic analysis for the Global Burden of Disease Study 2010 Lancet Dec 15;380(9859): (4) IMS Midas; CHF/MNF, MAT 2016-Q3; Average exchange rates 2016; Data adjusted for hyperinflation in Venezuela. 8

9 A Vifor Pharma Exploiting the potential of IV iron outside dialysis through market awareness Worldwide market Swiss market 8% 4% 12% Gynaecology Internal Medicine Nephrology 30% 70% Nephrology segment 9% 38% Cardiology Oncology/Hematology Geriatry 25% Gastroenterology Other TA's 9

10 B Fresenius Medical Care Renal Pharma The Journey ESTABLISH BUILD PORTFOLIO ENHANCE VALUE

11 B Vifor Fresenius Medical Care Renal Pharma Establish Strong Iron and Pharma Expertise 55% Stake CCX140 Avacopan/ CCX168 Global Leader in Dialysis 45% Stake 11

12 B Vifor Fresenius Medical Care Renal Pharma Building Portfolio Mircera /Roche US Licence EU Affiliates Acquisition from FMC CCX168/ ChemoCentryx Licence (Europe & other) Retacrit /Pfizer US Licence Veltassa /Relypsa Licence (excl. US & Japan) Rayaldee /OPKO Licence (Europe & other) CCX140/ ChemoCentryx Licence (ex-us/china) Q Q Q Q Q Q Q

13 B Vifor Fresenius Medical Care Renal Pharma Enhance Value Focus on Therapeutic Areas Anaemia Management Mineral & Bone Management Cardio-Renal Management Kidney Protection Avacopan/ CCX168 CCX140 Disease modifying CKD progression Rare Glomerular Diseases 13

14 C Vifor Pharma Veltassa Blockbuster potential >USD 1 billion 6 Strong intellectual property 1 Innovative product 2 High unmet medical need 5 3 Broad label 4 Uniquely differentiated & well tolerated Large market opportunity 14

15 C Vifor Pharma Veltassa Hyperkalemia may lead to arrhythmias and increases the risk of death Odds of Death within 24 Hour Period 1 % Of US physicians who would take action at/above serum K + level (Split by Specialty and Stage of CKD) Odds Ratio of Death from Hyperkalemia % of doctors taking action Potassium level, meq/l Serum K + levels Treatment Algorithm Quantitative Study, June 2013, n=386 1 Retrospective Analysis of 245,808 Veterans; adapted from Einhorn et al., 169 (vol 12) Arch Intern. Med (June 22, 2009). 15

16 C Vifor Pharma Veltassa Encouraging initial demand in '000 YTD Scripts Dispensed to Patients and Units Sold to Hospitals/Institutions in the US 2016 Prescriptions dispensed to patients and units sold to hospitals / institutions 4'000 3'000 2'000 1' Outpatient TRx Non-retail units Retail TRx: Outpatient prescriptions covered and dispensed Non-Retail Units: Hospital/institution units sold 16

17 Vifor Pharma Vision Global Leader in Iron Deficiency, Nephrology and Cardio-Renal Therapies. 17